MONDAY, June 23, 2025 (HealthDay News) — For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like peptide 1 receptor agonist, ecnoglutide, yields a superior and sustained reduction in body weight versus placebo, according to a study published online June 21 in The Lancet Diabetes & Endocrinology to coincide with […]
The post ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight first appeared on Physician’s Weekly.
